HIGHLIGHTS
- who: Diego Luigi Cortinovis et al. from the University of Pu00e9cs, Hungary University of Pittsburgh, United States have published the research work: Harnessing DLL3 inhibition: From old promises to new therapeutic horizons, in the Journal: (JOURNAL)
- what: The aim of the study was to assess the safety of ROVA-T; secondary objectives were to characterize the pharmacokinetics and immunogenicity of ROVA-T, estimate its antitumor activity, and establish the recommended phase II dose and schedule. The aim was to assess safety and tolerability; secondary objectives were frontiersin.org 10.3389/fmed.2022.989405 because OS . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.